Cedars-Sinai performs more than 250 kidney transplants per year. According to Irene Kim, MD, 30 percent of these patients have a highly sensitized immune system, causing them to reject the transplant due to the antibodies their bodies produce. Determined to make kidney transplants an option for everyone, researchers at Cedars-Sinai have discovered a new pathway to treat patients with antibody rejection. In this episode, Dr. Kim discusses her involvement in discovering this specialized therapy.
Learn more about Dr. Irene Kim at [ Ссылка ]
Learn more about Dr. Bruce Gewertz: [ Ссылка ]
For Healthcare Professionals: To claim CME credit for this activity, please click the link to be redirected to the Cedars-Sinai CME Portal at [ Ссылка ]
Connect with us:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars- Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow’s health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents.
